Related posts
Nervous markets await NvidiaCharles River Labs Intl is a American stock, trading under the symbol CRL-N on the New York Stock Exchange (CRL). It is usually referred to as NYSE:CRL or CRL-N
In the last year, there was no coverage of Charles River Labs Intl published on Stockchase.
Charles River Labs Intl was recommended as a Top Pick by on . Read the latest stock experts ratings for Charles River Labs Intl.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
0 stock analysts on Stockchase covered Charles River Labs Intl In the last year. It is a trending stock that is worth watching.
On 2025-05-05, Charles River Labs Intl (CRL-N) stock closed at a price of $119.44.
CRL provides drug discovery and safety testing services and is now trading at 22.6 times' Forward P/E (historical averages range from 19x to 33x). In the last five years, revenue growth was quite healthy, averaging around 12% on average, largely driven through acquisitions. The balance sheet is slightly leveraged, with net debt of $2.8B and net debt/EBITDA of around 2.7x. The company has been growing and repurchasing shares over the last few years. It is a solid company in our view, but as might be expected the valuation is a little expensive given the high quality of the business (not excessive though at 22X earnings). Based on consensus estimates, sales are expected to grow by 2% this year and then normalize to around 7% over the next few years. Overall, an interesting name with strong growth and healthy cash generation. We would be comfortable owning it.
Unlock Premium - Try 5i Free